DrugCite
Search

PEG INTRON

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Peg Intron Adverse Events Reported to the FDA Over Time

How are Peg Intron adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Peg Intron, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Peg Intron is flagged as the suspect drug causing the adverse event.

Most Common Peg Intron Adverse Events Reported to the FDA

What are the most common Peg Intron adverse events reported to the FDA?

Anaemia
1236 (1.95%)
Fatigue
1162 (1.84%)
Nausea
1149 (1.82%)
Dehydration
1089 (1.72%)
Weight Decreased
1076 (1.7%)
Vomiting
1047 (1.65%)
Asthenia
902 (1.42%)
Depression
867 (1.37%)
White Blood Cell Count Decreased
775 (1.22%)
Pyrexia
753 (1.19%)
Dizziness
663 (1.05%)
Show More Show More
Dyspnoea
655 (1.03%)
Diarrhoea
651 (1.03%)
Headache
648 (1.02%)
Insomnia
625 (.99%)
Platelet Count Decreased
580 (.92%)
Haemoglobin Decreased
537 (.85%)
Malaise
517 (.82%)
Pain
501 (.79%)
Loss Of Consciousness
454 (.72%)
Decreased Appetite
453 (.72%)
Fall
410 (.65%)
Condition Aggravated
405 (.64%)
Anxiety
399 (.63%)
Anorexia
389 (.61%)
Influenza Like Illness
387 (.61%)
Chest Pain
371 (.59%)
Pneumonia
365 (.58%)
Rash
361 (.57%)
Alopecia
345 (.55%)
Confusional State
330 (.52%)
Arthralgia
319 (.5%)
Feeling Abnormal
319 (.5%)
Red Blood Cell Count Decreased
301 (.48%)
Memory Impairment
297 (.47%)
Chills
296 (.47%)
Dysgeusia
284 (.45%)
Back Pain
276 (.44%)
Pruritus
270 (.43%)
Abdominal Pain Upper
244 (.39%)
Aspartate Aminotransferase Increase...
244 (.39%)
Injection Site Erythema
244 (.39%)
Suicidal Ideation
243 (.38%)
Alanine Aminotransferase Increased
236 (.37%)
Myalgia
233 (.37%)
Hyperhidrosis
227 (.36%)
Tremor
221 (.35%)
Pain In Extremity
219 (.35%)
Abdominal Pain
212 (.33%)
Oedema Peripheral
210 (.33%)
Convulsion
206 (.33%)
Anger
205 (.32%)
Hypoaesthesia
197 (.31%)
Dry Mouth
194 (.31%)
Hypotension
192 (.3%)
Irritability
192 (.3%)
Hypertension
187 (.3%)
Drug Ineffective
185 (.29%)
Blood Potassium Decreased
182 (.29%)
Cough
182 (.29%)
Muscle Spasms
172 (.27%)
Dry Skin
169 (.27%)
Amnesia
166 (.26%)
Haematemesis
166 (.26%)
Gait Disturbance
164 (.26%)
Epistaxis
162 (.26%)
Ascites
160 (.25%)
Renal Failure
160 (.25%)
Vision Blurred
158 (.25%)
Somnolence
157 (.25%)
Blood Pressure Increased
155 (.24%)
Constipation
155 (.24%)
Thrombocytopenia
153 (.24%)
Sepsis
152 (.24%)
Blood Glucose Increased
150 (.24%)
Blood Bilirubin Increased
145 (.23%)
Hepatic Failure
144 (.23%)
Neutropenia
142 (.22%)
Syncope
141 (.22%)
Disturbance In Attention
136 (.21%)
Aggression
131 (.21%)
Erythema
128 (.2%)
Crying
127 (.2%)
Bronchitis
126 (.2%)
Staphylococcal Infection
126 (.2%)
Heart Rate Increased
124 (.2%)
Abdominal Distension
121 (.19%)
Haematocrit Decreased
120 (.19%)
Pancytopenia
120 (.19%)
Contusion
119 (.19%)
Hepatic Cirrhosis
119 (.19%)
Blood Pressure Decreased
118 (.19%)
Neutrophil Count Decreased
118 (.19%)
Pulmonary Embolism
117 (.18%)
Rectal Haemorrhage
117 (.18%)
Drug Exposure During Pregnancy
115 (.18%)
Jaundice
115 (.18%)
Death
114 (.18%)
Palpitations
114 (.18%)
Influenza
113 (.18%)
Cellulitis
110 (.17%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Peg Intron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Peg Intron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Peg Intron

What are the most common Peg Intron adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Peg Intron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Peg Intron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Peg Intron According to Those Reporting Adverse Events

Why are people taking Peg Intron, according to those reporting adverse events to the FDA?

Hepatitis C
9812
Product Used For Unknown Indication
252
Drug Use For Unknown Indication
232
Hepatitis
111
Hepatitis B
102
Malignant Melanoma
76
Show More Show More
Chronic Hepatitis
43
Metastatic Malignant Melanoma
35
Hepatic Cirrhosis
34
Hereditary Haemorrhagic Telangiecta...
30
Hepatitis C Virus
23
Bone Sarcoma
21
Hepatitis C Virus Test
14
Drug Exposure During Pregnancy
13
Multiple Myeloma
10
Polycythaemia Vera
7
Renal Cell Carcinoma Stage Unspecif...
7
Chronic Myeloid Leukaemia
7
Non-hodgkins Lymphoma
6
Hepatitis D
6
Hepatitis Viral
6
Chronic Leukaemia
5
Carcinoid Tumour
5
Myelofibrosis
4
Disease Recurrence
4
Renal Cancer Metastatic
4
Metastatic Renal Cell Carcinoma
4
Pregnancy
3
Leukaemia
3
Hairy Cell Leukaemia
3
Lymphoma
3
Neurofibromatosis
3
Liver Disorder
3
Ill-defined Disorder
3
Antiviral Prophylaxis
3
Cardiac Failure Congestive
3
Plasmacytoma
3
Hiv Infection
3
Atrial Fibrillation
3
Hepatic Neoplasm Malignant
3
Small Intestine Carcinoma
3
Malignant Melanoma Stage Iv
2
Arthritis
2
Prophylaxis
2
Off Label Use
2
Carcinoma
2
Cryoglobulinaemia
2
Hepatitis Post Transfusion
2
Hepatitis Cholestatic
2
Viraemia
2
Renal Cell Carcinoma
2

Peg Intron Case Reports

What Peg Intron safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Peg Intron. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Peg Intron.